Notify me when Healthcare Value Capital, LLC files a new 13F portfolio report.
⭐ Subscribe ⭐| Quarter | Holdings | Value $ | Bought | Sold | Net | Top Holdings | Form Type | Filing Time |
|---|---|---|---|---|---|---|---|---|
| Q3 2021 | 18 | $38,529,000 | +$2,444,600 | -$7,662,583 | -$5,217,983 | GILD, GSK, PFE, ALKS, AMYT | 13F-HR | 12 Nov 2021, 19:56 |
| Q2 2021 | 18 | $46,240,000 | +$9,125,650 | -$1,299,000 | +$7,826,650 | GILD, GSK, PFE, ALKS, BMY | 13F-HR | 16 Aug 2021, 11:28 |
| Q1 2021 | 18 | $39,175,000 | +$23,683,667 | -$12,840,500 | +$10,843,167 | GILD, PFE, GSK, CLVSQ, VYNE | 13F-HR | 17 May 2021, 08:27 |
| Q4 2020 | 13 | $25,924,000 | +$736,000 | -$4,651,500 | -$3,915,500 | ABBV, GSK, VYNE, GILD, TYME | 13F-HR | 16 Feb 2021, 13:48 |
| Q3 2020 | 13 | $27,293,000 | +$5,131,600 | -$9,371,000 | -$4,239,400 | GSK, JAZZ, GILD, ABBV, VYNE | 13F-HR | 16 Nov 2020, 09:48 |
| Q2 2020 | 15 | $34,719,000 | +$3,810,000 | -$17,991,474 | -$14,181,474 | GSK, GILD, SPXU, MNLO, TYME | 13F-HR | 14 Aug 2020, 09:13 |
| Q1 2020 | 18 | $47,240,000 | +$25,263,067 | -$6,149,200 | +$19,113,867 | ABBV, GSK, GILD, SPXU, CAH | 13F-HR | 15 May 2020, 08:47 |
| Q4 2019 | 13 | $32,003,000 | +$803,143 | -$5,928,095 | -$5,124,952 | GSK, GILD, ABBV, CVS, TYME | 13F-HR | 14 Feb 2020, 14:02 |
| Q3 2019 | 16 | $32,513,000 | +$16,784,000 | -$3,479,100 | +$13,304,900 | GILD, GSK, ABBV, CVS, WBA | 13F-HR | 14 Nov 2019, 11:56 |
| Q2 2019 | 8 | $21,468,000 | +$7,335,476 | -$5,150,000 | +$2,185,476 | GSK, GILD, TYME, GNLN, PFE | 13F-HR | 14 Aug 2019, 10:46 |
| Q1 2019 | 8 | $21,818,000 | +$6,917,000 | -$7,328,000 | -$411,000 | AGN, GSK, TYME, GILD, VKTX | 13F-HR | 14 May 2019, 17:09 |
| Q4 2018 | 8 | $24,838,000 | +$678,121 | -$15,456,500 | -$14,778,379 | TYME, LAB, GSK, BIS, AGN | 13F-HR | 13 Feb 2019, 12:01 |
| Q3 2018 | 11 | $41,111,000 | +$782,023 | -$1,707,179 | -$925,156 | GILD, AMRN, TYME, GSK, AGN | 13F-HR | 13 Nov 2018, 17:49 |
| Q2 2018 | 11 | $34,708,000 | +$10,035,121 | $0 | +$10,035,121 | GILD, TYME, NVLNF, GSK, AGN | 13F-HR | 07 Aug 2018, 16:13 |
| Q1 2018 | 8 | $23,003,000 | +$2,944,750 | $0 | +$2,944,750 | GILD, TYME, NVLNF, LAB, GSK | 13F-HR | 27 Apr 2018, 17:13 |
| Q4 2017 | 8 | $28,464,000 | +$848,426 | -$12,978,000 | -$12,129,574 | TYME, GILD, NVLNF, LAB, AMRN | 13F-HR | 23 Jan 2018, 13:05 |
| Q3 2017 | 9 | $42,144,000 | +$14,206,027 | -$6,138,000 | +$8,068,027 | TYME, PFE, NVLNF, GILD, DEPO | 13F-HR | 13 Nov 2017, 10:23 |
| Q2 2017 | 9 | $37,302,000 | +$3,099,320 | -$7,119,000 | -$4,019,680 | PFE, NVLNF, DEPO, GILD, AGN | 13F-HR | 10 Aug 2017, 15:10 |
| Q1 2017 | 12 | $43,085,000 | +$1,597,000 | -$15,314,000 | -$13,717,000 | NVLNF, PFE, GILD, DEPO, AMRI | 13F-HR | 12 May 2017, 15:30 |
| Q4 2016 | 14 | $58,301,000 | +$22,541,667 | -$14,928,802 | +$7,612,865 | ANIP, PFE, NVLNF, DEPO, AMRI | 13F-HR | 10 Feb 2017, 10:53 |
| Q3 2016 | 15 | $54,074,000 | +$3,414,000 | -$14,763,083 | -$11,349,083 | ANIP, DEPO, PFE, DGX, AMRI | 13F-HR | 10 Nov 2016, 15:02 |
| Q2 2016 | 14 | $54,597,000 | +$1,567,913 | -$7,084,930 | -$5,517,017 | ANIP, DEPO, PFE, DGX, AORT | 13F-HR | 15 Aug 2016, 12:18 |
| Q1 2016 | 16 | $49,343,000 | +$6,816,317 | -$1,412,000 | +$5,404,317 | ANIP, AMRI, PFE, DEPO, DGX | 13F-HR | 16 May 2016, 12:13 |
| Q4 2015 | 15 | $53,628,000 | +$4,294,625 | -$10,979,357 | -$6,684,732 | ANIP, AMRI, QLTI, PFE, DGX | 13F-HR | 16 Feb 2016, 14:53 |
| Q3 2015 | 20 | $55,973,000 | +$11,252,108 | -$9,675,885 | +$1,576,223 | ANIP, AMRI, AZN, QLTI, PFE | 13F-HR | 16 Nov 2015, 10:57 |
| Q2 2015 | 22 | $69,208,000 | +$22,079,055 | -$20,708,653 | +$1,370,402 | AMRI, QLTI, ANIP, AZN, PFE | 13F-HR | 14 Aug 2015, 09:47 |
| Q1 2015 | 25 | $66,967,000 | +$16,286,779 | -$2,719,226 | +$13,567,553 | AMRI, TWM, AZN, TEVA, DGX | 13F-HR | 14 May 2015, 14:57 |
| Q4 2014 | 19 | $49,362,000 | +$10,059,384 | -$27,755,732 | -$17,696,348 | AMRI, AZN, TEVA, DGX, PFE | 13F-HR | 13 Feb 2015, 13:13 |
| Q3 2014 | 23 | $69,276,000 | +$26,635,418 | -$20,013,186 | +$6,622,232 | TWM, AMRI, ANIP, B108PS, TEVA | 13F-HR | 13 Nov 2014, 11:15 |
| Q2 2014 | 25 | $64,841,000 | +$15,316,389 | -$10,817,851 | +$4,498,538 | AMRI, AZN, ANIP, TEVA, AUXL | 13F-HR | 13 Aug 2014, 16:14 |
| Q1 2014 | 27 | $62,700,000 | +$24,487,585 | -$35,724,880 | -$11,237,295 | AMRI, TEVA, AUXL, DGX, MRK | 13F-HR | 13 May 2014, 12:24 |
| Q4 2013 | 23 | $61,604,000 | $0 | $0 | $0 | ANIP, SUPN, AUXL, AZN, FRX | 13F-HR | 13 Feb 2014, 09:15 |